Greater esterification and retention of budesonide in the airways and lung as compared to ciclesonide after repeated intratracheal administration in vivo Source: Eur Respir J 2004; 24: Suppl. 48, 345s Year: 2004
Esterification prolongs retention of budesonide but not ciclesonide - active principle in rat trachea Source: Eur Respir J 2005; 26: Suppl. 49, 369s Year: 2005
In vitro metabolism of ciclesonide, beclomethasone dipropionate, budesonide and fluticasone propionate in human precision-cut lung slicesSource: Eur Respir J 2005; 26: Suppl. 49, 255s Year: 2005
Budesonide is better retained in airway tissue than fluticasone propionate and mometasone furoate due to the formation of lipophilic, slowly hydrolyzed budesonide esters Source: Eur Respir J 2003; 22: Suppl. 45, 281s Year: 2003
Evidence of in vivo esterification of budesonide in humans Source: Eur Respir J 2005; 26: Suppl. 49, 370s Year: 2005
Relationship between the inhaled and pulmonary absorbed dose of budesonide and mometasone furoate: A study in the isolated perfused rat lung Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Budesonide is retained in the airways longer than mometasone furoate due to the reversible formation of lipophilic budesonide fatty acid esters - significance for asthma therapy Source: Eur Respir J 2002; 20: Suppl. 38, 53s Year: 2002
Synergistic interaction between beclomethasone diproprionate and formoterol fumarate in an ex vivo model of bronchial asthma Source: International Congress 2018 – Basic pharmacology Year: 2018
Tissue accumulation kinetics of ciclesonide-active metabolite and budesonide in mice Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008
Budesonide esterification in human bronchial epithelial cells is not impaired by formoterol Source: Eur Respir J 2002; 20: Suppl. 38, 619s Year: 2002
Exposure of human subcutaneous adipose tissue and skeletal muscle tissue to unbound active drug after inhalation of high-dose ciclesonide or budesonide Source: Eur Respir J 2007; 30: Suppl. 51, 351s Year: 2007
Deposition and metabolism of inhaled ciclesonide in the human lung Source: Eur Respir J 2010; 36: 1113-1119 Year: 2010
Inhibitory effects of formoterol, budesonide and tiotropium bromide on human neutrophils in vitro Source: Eur Respir J 2003; 22: Suppl. 45, 286s Year: 2003
Reversible intracellular esterification increases budesonide airway selectivity Source: Eur Respir J 2001; 18: Suppl. 33, 158s Year: 2001
Unbound pharmacologically active metabolite des-CIC is not detectable in human skeletal muscle and subcutaneous adipose tissue after inhalation of high-dose ciclesonide Source: Eur Respir J 2006; 28: Suppl. 50, 666s Year: 2006
Concentrations of ciclesonide and its metabolites in the human lung after inhalation of 1280 μg ciclesonide Source: Eur Respir J 2006; 28: Suppl. 50, 212s Year: 2006
Efficient deposition and absorption of orally inhaled indacaterol in the lungs Source: Annual Congress 2011 - COPD management Year: 2011
Different tissue accumulation kinetics of ciclesonide-active metabolite and budesonide in mice Source: Eur Respir J 2006; 28: Suppl. 50, 433s Year: 2006
Determination of tissue concentrations of metabolites in surgical preparations following inhalation of beclomethasone-dipropionate using conventional and extrafine aerosols Source: Eur Respir J 2003; 22: Suppl. 45, 472s Year: 2003
High lung deposition of 99m Tc-labelled ciclesonide administered via HFA-MDI to asthma patients Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004